Needham & Company
View Older Stories
-
Progenics Pharma (PGNX) Prices 9.09M Share Common Offering at $8.25/Sh
-
Progenics Pharmaceuticals Announces Pricing of Public Offering of Common Stock
-
Progenics Pharmaceuticals Announces Pricing of Public Offering of Common Stock
-
Progenics Pharmaceuticals (PGNX) PT Raised to $16 at Needham & Company
-
Progenics Pharmaceuticals to Present at the 17th Annual Needham Healthcare Conference
-
Progenics Pharmaceuticals to Present at the 17th Annual Needham Healthcare Conference
-
Progenics Pharma (PGNX): Updated Azedra Data Support Broad Efficacy - Needham
-
Progenics Pharma (PGNX): Expert Meeting Indicates Likely Positive Results For Azedra - Needham
-
Needham Warming to Progenics Pharma (PGNX) After NDR
-
Progenics Pharmaceuticals to Present at the 16th Annual Needham Healthcare Conference
-
Needham and Company Maintains Buy Rating and $14 PT on Progenics Pharmaceuticals (PGNX); Azedra Clears Efficacy Hurdle
-
Pre-Open Movers 02/06: (GALE) (HAS) (COG) Higher; (TIF) (IP) (BLUE) Lower (more...)
-
Needham & Company Upgrades Progenics Pharmaceuticals (PGNX) to Strong Buy
-
Needham & Company Reiterates Bullis View on Progenics Pharmaceuticals (PGNX) as SPECT/CT Imaging Agent Passes Interim Analysis
-
Progenics Pharma (PGNX): Reiterating Top Pick For 2017 - Needham
-
Progenics Pharma (PGNX): Profitability Could Come In '17 - Needham
-
Oral Relistor Approval the First of Many Progenics Pharmaceuticals (PGNX) Drivers - Needham & Company
-
Needham & Company Weighs in on Brexit Biotech Impact (ACAD) (GILD0 (ICPT) (SGEN)
-
Progenics Pharmaceuticals to Present at the 15th Annual Needham Healthcare Conference
-
Needham & Company Defends Progenics (PGNX) on PDUFA Delay, Valeant Overhang
-
Needham & Company Reiterates Buy on Progenics Pharma (PGNX); Anticipates Oral Relistor Approval
-
Progenics (PGNX) PT Lifted at Needham & Company on Relistor Tailwinds, Expanded Imaging Pipeline
-
Progenics Pharmaceuticals to Present at 14th Annual Needham Healthcare Conference
-
Needham & Company Positive on Relistor Expanding Approveal for Progenics Pharmaceuticals (PGNX)
-
Progenics Pharmaceuticals CEO, Mark R. Baker, to Present at 13th Annual Needham Healthcare Conference
-
Progenics (PGNX) Prices 7.6M Offering at $4.60/Share
-
Progenics Pharmaceuticals Announces Pricing of Public Offering of Common Stock
-
Pre-Open Stock Movers 2/3: (KTOS) (PGNX) (ARTC) Higher; (UNTD) (GALE) (SFY) Lower (more...)
-
Needham & Company Upgrades Progenics Pharmaceuticals (PGNX) to Buy on Positive PSMA Data at ASCO-GU
-
Pre-Open Stock Movers 1/29: (VRNG) (FSL) (DOW) Higher; (PGNX) (TUP) (BA) Lower (more...)
-
Notable Analyst Rating Changes 07/08: (BBRY) (LINE) (PGNX) Upgraded; (SSRI) (BSX) (INTC) Downgraded
-
Progenics (PGNX) Prices 8.5M Common Stock Offering
-
Needham & Company Downgrades Progenics Pharmaceuticals (PGNX) to Hold; Concerns on Lack of Clarity with Relistor
-
Needham & Company Reiterates a 'Buy' on Progenics Pharmaceuticals (PGNX);
-
Needham Upgrades Progenics Pharma (PGNX) to Buy
-
Needham & Company Maintains a 'Hold' on Progenics Pharmaceuticals (PGNX); In Waiting Mode
-
Needham Cuts Progenics (PGNX) to Hold Midday